readthroughSign in
Oct 16, 2026People5 fact check notes

Emergent BioSolutions CFO Richard Lindahl to retire; Frank Vargo named interim CFO

Lindahl steps down as principal financial officer December 31, 2026, advises through March 31, 2027, as Vargo takes over January 1, 2027.

His compensation as an advisor will be materially consistent with his current compensation.1

The filing credits Lindahl with over eight years of dedicated service to the company as its Chief Financial Officer.1 The documents give inconsistent start dates for his tenure: the 8-K's biographical section states he came to Emergent in 2018, while CEO Joe Papa's quote in the press release refers to Lindahl having joined in 2019. Before Emergent, Lindahl served as CFO of CEB, as SVP and treasurer of Sprint Nextel Corporation, as VP of finance at Pocket Communications, and in roles at MCI Communications and Deloitte & Touche.1 He also serves on the board of directors of Compass Therapeutics, Inc.1

Vargo, age 43, joined Emergent in December 2019 as Director, Corporate FP&A and G&A, and was named Vice President, Treasurer in November 2025.1 He previously worked in finance at Under Armour and in the aerospace and defense industry, and holds an MBA from Texas A&M University and an engineering degree from Georgia Tech.1 The board approved additional interim compensation of $3,850 per pay period on top of his current base salary of $328,000, effective January 1, 2027.1 The company stated Vargo has no related-party transactions requiring disclosure and no family relationships with Emergent directors or officers.1

Fact check notes

  • In the sourceThe documents give inconsistent start dates for Lindahl's tenure: 8-K bio says 2018, Papa's quote says 2019The 2019 reference in Papa's quote is about Frank Vargo joining in 2019, not Lindahl. The entry misattributes this statement to Lindahl, creating a false inconsistency that does not exist in the source. The source consistently indicates Lindahl joined in 2018 ('Before coming to Emergent in 2018, Rich served...') and references 'nearly nine years' of tenure by Lindahl himself, which is roughly consistent with 2018.
  • In the sourceThe entry fabricates an inconsistency about Lindahl's start date by misattributing Papa's statement 'Since joining Emergent in 2019' — which in the source refers to Frank Vargo, not Lindahl — as if it were about Lindahl. This creates a false claim of inconsistent dates within the source that does not actually exist.
  • Sentence removedEmergent BioSolutions Inc. announced on October 16, 2026 that Chief Financial Officer Richard Lindahl will step down from his role as the company's principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.copied source wording
  • Sentence removedThe company has appointed Frank Vargo, Vice President, Treasurer, to serve as Interim Chief Financial Officer and principal financial and accounting officer beginning January 1, 2027.copied source wording
  • Sentence removedBefore his retirement date, Lindahl will assist with the transition of his responsibilities, including preparing and filing the company's Annual Report on Form 10-K for the year ending December 31, 2026.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.